Bausch Health Cos Inc. (BHC) – What Are Analysts Saying About This Stock?

Bausch Health Cos Inc. (NYSE:BHC) has earned a consensus rating of “Reduce” from the seven brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and six have assigned a hold recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $8.25.

A number of analysts have recently weighed in on the stock. Royal Bank Of Canada upped their price target on shares of Bausch Health Cos from $9.00 to $10.00 and gave the stock a “sector perform” rating in a research note on Thursday, October 29th. Jefferies Financial Group lifted their price target on shares of Bausch Health Cos from $6.50 to $8.00 and gave the company a “hold” rating in a research report on Thursday, October 29th. Zacks Research lowered Bausch Health Cos from a “strong-buy” rating to a “hold” rating in a report on Thursday. Wall Street Zen raised Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 1st. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Bausch Health Cos in a report on Thursday, October 29th.

Bausch Health Cos Trading Up 3.0%

Shares of NYSE:BHC opened at $8.20 on Friday. The company’s 50 day moving average is $6.40 and its 200 day moving average is $5.74. Bausch Health Cos has a twelve month low of $4.33 and a twelve month high of $9.04. The company has a market cap of $3.07 billion, a PE ratio of -3.58 and a beta of 0.30.

Bausch Health Cos (NYSE:BHC) last announced its quarterly earnings data on Wednesday, October 28th. The company reported $1.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.52. The business had revenue of $2.90 billion during the quarter, compared to analysts’ expectations of $2.72 billion. Bausch Health Cos had a negative return on equity of 401.73% and a negative net margin of 7.57%. Equities research analysts predict that Bausch Health Cos will post 4.53 earnings per share for the current fiscal year.

Insider Transactions at Bausch Health Cos

In other news, insider Aimee Lenar sold 36,827 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $7.03, for a total value of $258,893.81. Following the transaction, the insider owned 334,853 shares of the company’s stock, valued at approximately $2,354,016.59. The trade was a 9.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is currently owned by company insiders.

Institutional Trading of Bausch Health Cos

Large investors have recently made changes to their positions in the stock. Paulson & CO. Inc. bought a new position in Bausch Health Cos in the second quarter valued at about $361,151,000. Royal Bank of Canada boosted its position in Bausch Health Cos by 24.9% in the first quarter. Royal Bank of Canada now owns 11,363,498 shares of the company’s stock worth $61,362,000 after purchasing an additional 2,262,894 shares during the last quarter. MFN Partners Management LP bought a new stake in Bausch Health Cos during the second quarter valued at $29,580,000. Dimensional Fund Advisors LP raised its stake in shares of Bausch Health Cos by 10.8% during the first quarter. Dimensional Fund Advisors LP now owns 3,604,818 shares of the company’s stock valued at $19,456,000 after acquiring an additional 350,823 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Bausch Health Cos by 10.0% during the first quarter. Renaissance Technologies LLC now owns 1,575,772 shares of the company’s stock valued at $8,509,000 after buying an additional 143,581 shares during the last quarter. Institutional investors own 78.65% of the company’s stock.

Bausch Health Cos Company Profile

Bausch Health Companies Inc (NYSE:BHC) is a multinational specialty pharmaceutical company focused on developing, manufacturing and commercializing branded, generic and over-the-counter medicines. Its portfolio serves several therapeutic areas, including gastroenterology, dermatology, neurology, ophthalmology, hospital products and other specialty-care markets.

The company markets products through businesses such as Salix Pharmaceuticals, Ortho Dermatologics, Solta Medical and its international pharmaceutical operations.